Gamgertamig

DB22765InvestigationalProtein Based Therapies

OM336 is under investigation in clinical trial NCT07083960 (OM336 in Autoimmune Cytopenias).

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 17 and T-cell surface glycoprotein CD3
Curator reviewed
Code names: OM336

Resolves to

Compound

Targets

What you can answer from here — as of September 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Gamgertamig, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.